The global PD-1 and PD-L1 inhibitors market is poised to grow by USD 21.2 billion during 2019-2023, progressing at a CAGR of over 19% during the forecast period. Request Free Sample Pages
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200117005292/en/
Technavio has announced its latest market research report titled global PD-1 and PD-L1 inhibitors market 2019-2023. (Graphic: Business Wire)
Read the 118-page research report with TOC on "PD-1 and PD-L1 Inhibitors Market Analysis Report by Application (Solid tumors and Blood-related tumors), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023".
The proven efficiency of PD-1 and PD-L1 inhibitors and strong pipeline are among factors anticipated to boost the growth of the market.
PD-1 inhibitor such as KEYTRUDA exhibits superior efficacy over other approved therapies. This led to the approval of KEYTRUDA in September 2014, driving growth in the oncology therapeutics market. In clinical trials, PD-1 and PD-L1 inhibitors have shown higher overall survival rate (OSR), objective response rate (ORR), and progression-free survival (PFS) in patients with cancer such as melanoma and NSCLC. PD-1 and PD-L1 inhibitors are also used to inhibit cancer cells and reverse the damage caused by blocking the pathway that helps in cancer cell multiplication. As a result, most of the PD-1 inhibitor drugs are approved for cancer indications such as Hodgkin lymphoma, urogenital cancer, and NSCLC because they have high safety profile. Thus, the proven efficiency of PD-1 and PD-L1 inhibitors is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five PD-1 and PD-L1 Inhibitors Market Companies:
AstraZeneca is headquartered in the UK and operates the business under the Biopharmaceuticals segment. The company offers IMFINZI, which is a PD-L1 inhibitor approved for the treatment of NSCLC and urothelial carcinoma.
Bristol-Myers Squibb is headquartered in the US and offers products through the BioPharmaceuticals business unit. The company offers OPDIVO, which is a PD-1 inhibitor approved for the treatment of advanced small cell lung cancer, NSCLC, metastatic melanoma, renal cell carcinoma, and various other types of cancers.
F. Hoffmann-La Roche
F. Hoffmann-La Roche is headquartered in Switzerland and operates under various business segments, namely Pharmaceuticals and Diagnostics. The company offers TECENTRIQ, which is a PD-L1 inhibitor approved for the treatment of NSCLC.
Merck is headquartered in the US and offers products through the following business segments: Pharmaceutical, Animal health, Healthcare services, and Alliances. The company offers KEYTRUDA, which is a PD-1 inhibitor approved for the treatment of Hodgkin's lymphoma, urothelial cancer, melanoma, head and neck squamous cell cancer, NSCLC, and other types of cancers.
Pfizer is headquartered in the US and offers products through the following business segments: Innovative health and Essential health. The company offers BAVENCIO, which is a PD-L1 inhibitor approved for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform
PD-1 and PD-L1 Inhibitors Application Outlook (Revenue, USD Million, 2019 - 2023)
- Solid tumors
- Blood-related tumors
PD-1 and PD-L1 Inhibitors Regional Outlook (Revenue, USD Million, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care include:
MEK Inhibitors Market – Global MEK Inhibitors Market by product (MEKINIST, COTELLIC, and MEKTOVI) and geography (Asia, Europe, North America, and ROW).
Phosphodiesterase (PDE) inhibitors Market – Global Phosphodiesterase (PDE) inhibitors Market by application (oral, topical, and other RoA), and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.